Related Experiment Videos
Sweet's syndrome--therapy with cyclosporin
P von den Driesch1, C Steffan, A Zöbe
1Department of Dermatology, University of Erlangen-Nuremberg, Germany.
Clinical and Experimental Dermatology
|May 1, 1994
Summary
This case study shows cyclosporin A effectively treated Sweet's syndrome, a skin condition, following a respiratory infection. The treatment resolved symptoms rapidly and prevented recurrence, offering an alternative to traditional steroid therapies.
Area of Science:
- Dermatology
- Immunology
Background:
- Sweet's syndrome, an acute febrile neutrophilic dermatosis, is often associated with infections or other systemic conditions.
- Traditional treatments for Sweet's syndrome primarily involve systemic corticosteroids.
Observation:
- A 39-year-old female presented with Sweet's syndrome following an upper respiratory tract infection.
- The patient experienced skin lesions and general malaise.
Findings:
- Initial treatment with Cyclosporin A (10 mg/kg/day) led to rapid resolution of skin lesions and malaise within 9 days.
- The Cyclosporin A dose was successfully reduced within 21 days, with no recurrence of the eruption.
- Cyclosporin A, a T-lymphocyte inhibitor, also impacts granulocyte and monocyte functions, potentially explaining its efficacy.
Implications:
- Cyclosporin A presents a viable alternative treatment option for Sweet's syndrome, particularly for patients who may not tolerate or respond well to steroids.
- This case highlights the immunomodulatory effects of Cyclosporin A in managing neutrophilic dermatoses.